Skip to product information
Ribociclib – LuciRibo
KSh72,000.00
|
What it treats: |
Ribociclib is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor used in breast cancer treatment, very similar in class to palbociclib. |
|
Breast Cancer |
Hormone Receptor (HR)-Positive, HER2-Negative Advanced or Metastatic Breast Cancer In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men. In combination with fulvestrant in patients with disease progression after prior endocrine therapy. Approved for both premenopausal/perimenopausal and postmenopausal women, and in some regions, for men as well. |